PMI Impact Malaria

Burkina Faso



PMI Impact Malaria in Burkina Faso

PMI Impact Malaria (IM) is the flagship global service delivery project of the U.S. President’s Malaria Initiative (PMI). To fight malaria and save lives, IM is supporting Burkina Faso’s national malaria control program (NMCP) in its efforts to strengthen malaria service delivery.

In 2020, IM began working with Burkina Faso’s NMCP to monitor the efficacy of antimalarial medicines through a therapeutic efficacy study (TES). An earlier 2017-2018 TES conducted in the country showed that artemether-lumefantrine (AL), which currently serves as the first-line treatment for malaria, did not meet the efficacy threshold recommended by the World Health Organization.

The IM-supported TES in Burkina Faso is designed to determine whether the results of the previous study are reproducible and explore potential explanations for the increased rate in treatment failures. The study will also test alternatives to AL, such as combinations of dihydroartemisinin piperaquine (DHA- PPQ) or artesunate-pyronaridine (As-Pyr), which could replace AL as a first-line treatment in Burkina Faso, if need be. 


  • Burkina Faso Malaria Summary PMI Webpage
  • Malaria Service Delivery Photos PMI Impact Malaria Photo Library

Malaria Country Context

Burkina Faso’s entire population of about 19.2 million people is vulnerable to malaria. Malaria transmission in the country peaks during the rainy season from June through October, with variances based on geographic zones. The malaria parasite species Plasmodium falciparum causes the majority of infections.

Malaria continues to be a leading cause of illness and death in Burkina Faso, with an estimated 7.9 million cases and 27,800 deaths in 2018. According to the Ministry of Health, malaria accounts for 43% of consultations with a health provider and 22% of deaths.

The country’s national health system has a pyramid structure with the NMCP operating across all three levels: (1) the central level responsible for developing strategies, mobilizing resources, coordinating partners, monitoring implementation, and evaluating performance, (2) the intermediate level comprised of 13 health regions and eight regional hospitals, and (3) the peripheral level consisting of 70 health districts as well as district hospitals, medical centers, and primary health facilities.

To strengthen community health, Burkina Faso is rolling out a nationwide community health worker (CHW) program, with two CHWs per village. The CHWs are responsible for a wide range of activities, including prevention, diagnosis, and treatment of malaria, pneumonia, and diarrhea, along with distributing antimalarial medication during the country's seasonal malaria chemoprevention (SMC) campaign.


This is PMI Impact Malaria’s geographic coverage in Burkina Faso: 

Malaria prevalence in Burkina Faso:

Click here for a printable version of this page: English and French

Photo Credit: Allison Belemvire, PMI, Burkina Faso

Sources: PMI’s Burkina Faso Country Brief, PMI’s Burkina Faso Malaria Operational Plan FY 2019, 2019 World Malaria Report Burkina Faso Country Profile, PMI Impact Malaria Burkina Faso, and Burkina Faso’s NMCP